MIRCERA methoxy polyethylene glycol-epoetin beta 150 mcg solution for injection syringe

País: Austràlia

Idioma: anglès

Font: Department of Health (Therapeutic Goods Administration)

ingredients actius:

Methoxy polyethylene glycol-epoetin beta, Quantity: 0.15 mg

Disponible des:

Roche Products Pty Ltd

Designació comuna internacional (DCI):

Methoxy polyethylene glycol-epoetin beta

formulario farmacéutico:

Injection, solution

Composición:

Excipient Ingredients: monobasic sodium phosphate monohydrate; methionine; poloxamer; sodium sulfate; mannitol; water for injections

Vía de administración:

Intravenous, Subcutaneous

Unidades en paquete:

One (pre-filled syringe)

tipo de receta:

(S4) Prescription Only Medicine

indicaciones terapéuticas:

MIRCERA is indicated for the treatment of anaemia associated with chronic kidney disease (CKD).

Resumen del producto:

Visual Identification: clear, colourless to slightly yellowish; Container Type: Syringe; Container Material: Glass Type I Clear; Container Life Time: 3 Years; Container Temperature: Store at 2 to 8 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Estat d'Autorització:

Registered

Data d'autorització:

2009-07-28

Fitxa tècnica

1
Mircera 20220121
AUSTRALIAN PRODUCT INFORMATION
MIRCERA
® (METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA)
1.
NAME OF THE MEDICINE
Methoxy polyethylene glycol-epoetin beta
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Mircera 30 micrograms/0.3 mL solution for injection in pre-filled
syringe
Mircera 50 micrograms/0.3 mL solution for injection in pre-filled
syringe
Mircera 75 micrograms/0.3 mL solution for injection in pre-filled
syringe
Mircera 100 micrograms/0.3 mL solution for injection in pre-filled
syringe
Mircera 120 micrograms/0.3 mL solution for injection in pre-filled
syringe
Mircera 150 micrograms/0.3 mL solution for injection in pre-filled
syringe
Mircera 200 micrograms/0.3 mL solution for injection in pre-filled
syringe
Mircera 250 micrograms/0.3 mL solution for injection in pre-filled
syringe
Mircera 360 micrograms/0.6 mL solution for injection in pre-filled
syringe
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Solution for injection in pre-filled syringe.
The solution if clear and colourless to slightly yellowish and the pH
is 6.2
4.
CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Mircera is indicated for the treatment of anaemia associated with
chronic kidney disease (CKD).
4.2 DOSE AND METHOD OF ADMINISTRATION
DOSAGE
General
Use the lowest dose of Mircera that will gradually increase the
haemoglobin concentration. Mircera
is administered less frequently than Aranesp
®
, Eprex
®
and NeoRecormon
®
due to the longer
elimination half-life.
Treatment with Mircera is to be initiated under the supervision of a
healthcare professional.
Treatment of Anaemic Patients with Chronic Kidney Disease
The solution can be administered by subcutaneous (SC) or intravenous
(IV) injection, according to
clinical preference. Mircera can be injected SC in the abdomen, arm or
thigh. All three injection
sites are equally suitable for SC injection with Mircera.
Patients being changed from SC to IV administration of Mircera (or
vice-versa) should have their
haemoglobin levels monitored to ensure that t